Session Information
Date: Tuesday, November 10, 2026
Title: (2096-2128) Vasculitis - Non-ANCA-Associated & Related Disorders - Clinical Poster C
Session Type: Poster Session C
Session Time: 10:30AM-12:30PM
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a chronic, systemic fibroinflammatory disease characterized by unpredictable and recurrent flares, leading to progressive organ damage and decreased quality of life. Inebilizumab (INEB) is a humanized, glycoengineered CD19-directed monoclonal antibody that selectively depletes B cells, including plasmablasts and some plasma cells implicated in IgG4-RD pathogenesis. INEB was found to be safe and effective in the MITIGATE trial (NCT04540497), an international, randomized, double-blind, placebo (PBO)-controlled phase 3 trial (Stone et al., 2025). We present a subgroup analysis of the MITIGATE open-label period (OLP) evaluating the efficacy and safety of INEB in participants aged < 65 years and ≥65 years.
Methods: Eligible participants who completed the randomized controlled period (RCP) of the MITIGATE trial could enroll in an optional 3-year OLP. During the OLP, all enrolled participants received INEB 300 mg intravenously every 6 months after having received PBO (PBO/INEB group) or INEB (INEB/INEB group) in the preceding RCP. This post hoc subgroup analysis evaluated participant incidence of treated and adjudication committee (AC)-determined IgG4-RD flares, annualized flare rate, proportion of participants with glucocorticoid (GC) use for disease control, mean total GC use, and long-term safety in participants aged < 65 years and ≥65 years using data available at the time the last participant completed 1 year in the OLP.
Results: Of the 127 participants who completed RCP, 107 (84.3%) entered the OLP. Baseline characteristics were well balanced across the two treatment groups for both age subgroups. The median disease duration was 0.90 years (min 0.1, max 20.5) among < 65 years participants, and 0.65 years (min 0.1, max 8.5) among ≥65 years participants. During the first year of OLP, no participants in the INEB/INEB group experienced an IgG4-RD. In the PBO/INEB group, 3/38 (7.9%) participants (all < 65 years) experienced a flare during the OLP. The annualized flare rate was low in both age subgroups (Table 1). GC use remained low in the INEB/INEB group, with only 1/41 (2.4%) participants aged < 65 years requiring GCs, and no GC use was reported among any participants aged ≥65 years. No GC use (mean total dose) was observed among participants aged ≥65 years in the INEB/INEB group; mean total GC dose was 5.98 mg in those aged < 65 years (Table 1). TEAEs were generally comparable across age groups (< 65 vs ≥65 years), with numerically higher rates of nasopharyngitis, urinary tract infection, pyrexia, back pain, and lymphopenia among patients aged ≥65 years.
Conclusion: In the OLP of the MITIGATE trial, similar clinical benefit was observed across age-stratified subgroups (< 65 vs ≥65 years). INEB was associated with a reduced incidence of flares and lower GC use, demonstrating sustained clinical benefit. No new safety signals were identified in these subgroups relative to the RCP (Stone et al., NEJM 2024). These results suggest INEB may serve as a longer-term treatment option for IgG4-RD in both young and elderly participants.
To cite this abstract in AMA style:
Stone J, Culver E, Khosroshahi A, Zhang W, Della-Torre E, Okazaki K, Tanaka Y, Löhr M, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Ebbo M, Martínez-Valle F, Nayar M, Rebours V, Perugino C, Bray S, Wallace Z, Steed K, Osman M, Cheng S, Cimbora D. Efficacy and Safety of Inebilizumab for the Treatment of IgG4-RD Across Age Subgroups: Analysis from the Open-label Period of the MITIGATE Trial [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-inebilizumab-for-the-treatment-of-igg4-rd-across-age-subgroups-analysis-from-the-open-label-period-of-the-mitigate-trial/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-inebilizumab-for-the-treatment-of-igg4-rd-across-age-subgroups-analysis-from-the-open-label-period-of-the-mitigate-trial/

